These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38740306)

  • 1. Exploring G-quadruplex structure in PRCC-TFE3 fusion oncogene: Plausible use as anti cancer therapy for translocation Renal cell carcinoma (tRCC).
    Neha N; Das P
    J Biotechnol; 2024 Jul; 390():39-49. PubMed ID: 38740306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
    Neha ; Das P; Verma SP
    Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G-quadruplex structure at intron 2 of TFE3 and its role in Xp11.2 translocation and splicing.
    Verma SP; Das P
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):630-636. PubMed ID: 29138008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
    Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
    Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
    Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
    Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
    Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
    Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.
    Cao C; Lan X; Shang B; Jiang W; Guo L; Zheng S; Bi X; Zhou A; Sun Z; Shou J
    Clin Transl Oncol; 2022 Jul; 24(7):1333-1346. PubMed ID: 35118587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRCC-TFE3 regulates migration and invasion of translocation renal cell carcinomas via activation of Drp1-dependent mitochondrial fission.
    Wang B; Gan W; Han X; Li D
    Cell Biol Int; 2020 Aug; 44(8):1727-1733. PubMed ID: 32339358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.
    Xiong L; Chen X; Liu N; Wang Z; Miao B; Gan W; Li D; Guo H
    PLoS One; 2017; 12(9):e0185337. PubMed ID: 28949976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
    Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
    Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
    Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
    Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
    Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
    Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
    Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
    Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
    Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
    J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
    Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
    Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC.
    Wang B; Gan W; Han X; Liu N; Ma T; Li D
    Int J Biol Macromol; 2021 Apr; 176():437-447. PubMed ID: 33592266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
    Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
    Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
    Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
    J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
    Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
    Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMRK2 is an efficient diagnostic indicator for Xp11.2 translocation renal cell carcinoma.
    Feng H; Cao S; Fu S; Liu J; Gao Y; Dong Z; Cai T; Wen L; Xiong Z; Li S; Zhang X; Ma X; Li X
    J Pathol; 2024 Oct; 264(2):228-240. PubMed ID: 39092712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.